Concepts (119)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Triple Negative Breast Neoplasms | 10 | 2024 | 1215 | 1.340 |
Why?
|
| Breast Neoplasms | 17 | 2023 | 15694 | 1.130 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2024 | 1678 | 0.670 |
Why?
|
| Receptors, Estrogen | 3 | 2022 | 2086 | 0.540 |
Why?
|
| Receptor, ErbB-2 | 5 | 2023 | 2518 | 0.480 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 3 | 2024 | 521 | 0.430 |
Why?
|
| Molecular Targeted Therapy | 2 | 2020 | 2330 | 0.300 |
Why?
|
| Maytansine | 2 | 2020 | 38 | 0.300 |
Why?
|
| Proteomics | 3 | 2023 | 1380 | 0.260 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2020 | 1216 | 0.220 |
Why?
|
| Antineoplastic Agents | 2 | 2024 | 14289 | 0.220 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2023 | 15862 | 0.220 |
Why?
|
| Quinazolines | 2 | 2022 | 923 | 0.220 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2017 | 5178 | 0.220 |
Why?
|
| Paget's Disease, Mammary | 1 | 2020 | 41 | 0.190 |
Why?
|
| Female | 19 | 2023 | 141928 | 0.190 |
Why?
|
| Diarrhea | 1 | 2023 | 686 | 0.180 |
Why?
|
| Alpha Particles | 1 | 2019 | 26 | 0.180 |
Why?
|
| Pyrimidines | 3 | 2023 | 3518 | 0.170 |
Why?
|
| Breast Neoplasms, Male | 1 | 2020 | 229 | 0.170 |
Why?
|
| Mutation | 5 | 2023 | 15179 | 0.170 |
Why?
|
| Humans | 24 | 2024 | 261506 | 0.170 |
Why?
|
| Radium | 1 | 2019 | 93 | 0.160 |
Why?
|
| Neutropenia | 1 | 2023 | 968 | 0.160 |
Why?
|
| Phthalazines | 1 | 2019 | 253 | 0.150 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2019 | 224 | 0.150 |
Why?
|
| Immunoconjugates | 1 | 2020 | 279 | 0.150 |
Why?
|
| Gene Frequency | 1 | 2019 | 1163 | 0.140 |
Why?
|
| Breast | 2 | 2019 | 1344 | 0.140 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2023 | 882 | 0.140 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 3251 | 0.130 |
Why?
|
| Disease Progression | 2 | 2023 | 6682 | 0.130 |
Why?
|
| Carcinoma, Lobular | 1 | 2019 | 611 | 0.130 |
Why?
|
| Neoadjuvant Therapy | 6 | 2023 | 4975 | 0.120 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2019 | 840 | 0.120 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2019 | 2291 | 0.120 |
Why?
|
| Phenylurea Compounds | 1 | 2017 | 580 | 0.110 |
Why?
|
| Biomarkers, Tumor | 3 | 2022 | 10331 | 0.110 |
Why?
|
| Sarcoma | 1 | 2023 | 1725 | 0.110 |
Why?
|
| Transcriptome | 1 | 2021 | 1859 | 0.110 |
Why?
|
| Genetic Testing | 1 | 2020 | 1589 | 0.100 |
Why?
|
| Chemoradiotherapy | 1 | 2019 | 1946 | 0.100 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 2 | 2023 | 96 | 0.090 |
Why?
|
| Genomics | 1 | 2021 | 2738 | 0.090 |
Why?
|
| Trastuzumab | 1 | 2012 | 696 | 0.090 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 2 | 2023 | 182 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 2054 | 0.090 |
Why?
|
| Bone Neoplasms | 1 | 2019 | 2576 | 0.070 |
Why?
|
| Prospective Studies | 4 | 2023 | 12873 | 0.070 |
Why?
|
| Middle Aged | 6 | 2023 | 86204 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 8873 | 0.060 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2023 | 153 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2023 | 129 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2022 | 3890 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2023 | 198 | 0.050 |
Why?
|
| Neoplasms | 2 | 2019 | 15193 | 0.050 |
Why?
|
| Cyclins | 1 | 2023 | 456 | 0.050 |
Why?
|
| Anthracyclines | 1 | 2023 | 331 | 0.050 |
Why?
|
| Neurofibromin 1 | 1 | 2021 | 85 | 0.050 |
Why?
|
| Metaplasia | 1 | 2022 | 383 | 0.050 |
Why?
|
| B7 Antigens | 1 | 2021 | 84 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2023 | 7222 | 0.050 |
Why?
|
| Folate Receptor 1 | 1 | 2020 | 62 | 0.050 |
Why?
|
| Pyrroles | 1 | 2023 | 576 | 0.040 |
Why?
|
| Cation Transport Proteins | 1 | 2021 | 199 | 0.040 |
Why?
|
| Denosumab | 1 | 2019 | 68 | 0.040 |
Why?
|
| Radioisotopes | 1 | 2019 | 177 | 0.040 |
Why?
|
| Injections, Intravenous | 1 | 2019 | 573 | 0.040 |
Why?
|
| RNA, Neoplasm | 1 | 2021 | 771 | 0.040 |
Why?
|
| Retrospective Studies | 4 | 2022 | 37905 | 0.040 |
Why?
|
| BRCA2 Protein | 1 | 2019 | 358 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2023 | 4757 | 0.040 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2017 | 62 | 0.040 |
Why?
|
| Evolution, Molecular | 1 | 2021 | 834 | 0.040 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 992 | 0.040 |
Why?
|
| BRCA1 Protein | 1 | 2019 | 493 | 0.040 |
Why?
|
| Bone and Bones | 1 | 2019 | 619 | 0.030 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2023 | 1546 | 0.030 |
Why?
|
| Paclitaxel | 1 | 2023 | 1996 | 0.030 |
Why?
|
| Tamoxifen | 1 | 2019 | 876 | 0.030 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2021 | 986 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2019 | 1544 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 2021 | 1910 | 0.030 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2019 | 479 | 0.030 |
Why?
|
| Pyridines | 1 | 2022 | 1244 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2023 | 1471 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2021 | 1987 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2019 | 492 | 0.030 |
Why?
|
| B7-H1 Antigen | 1 | 2021 | 1022 | 0.030 |
Why?
|
| Contrast Media | 1 | 2021 | 1472 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2019 | 1046 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2019 | 1392 | 0.030 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2019 | 833 | 0.030 |
Why?
|
| Adult | 4 | 2020 | 77950 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2019 | 2283 | 0.030 |
Why?
|
| Piperazines | 1 | 2022 | 2101 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2019 | 2803 | 0.030 |
Why?
|
| Prognosis | 2 | 2021 | 21713 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2020 | 3981 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 2864 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 29902 | 0.020 |
Why?
|
| Cell Survival | 1 | 2017 | 3045 | 0.020 |
Why?
|
| Phenotype | 1 | 2021 | 6295 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 5112 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2021 | 3230 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2017 | 4804 | 0.020 |
Why?
|
| Animals | 2 | 2023 | 59536 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2021 | 3552 | 0.020 |
Why?
|
| Survival Rate | 1 | 2019 | 12221 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2021 | 7702 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2017 | 7226 | 0.020 |
Why?
|
| Aged | 2 | 2019 | 70117 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2017 | 14551 | 0.010 |
Why?
|
| Young Adult | 1 | 2019 | 21445 | 0.010 |
Why?
|
| Male | 2 | 2020 | 123000 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2020 | 32848 | 0.010 |
Why?
|
| Adolescent | 1 | 2019 | 31252 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2017 | 11965 | 0.010 |
Why?
|
| Child | 1 | 2019 | 29154 | 0.010 |
Why?
|